{"id":7688,"date":"2025-05-10T11:08:24","date_gmt":"2025-05-10T09:08:24","guid":{"rendered":"https:\/\/actualfarma.es\/congreso-2025\/?post_type=mesa&#038;p=7688"},"modified":"2025-06-06T10:31:35","modified_gmt":"2025-06-06T08:31:35","slug":"trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas","status":"publish","type":"mesa","link":"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/","title":{"rendered":"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama"},"content":{"rendered":"\n<p>Pilar Vicente. S. Farmacia. H. U. Ciudad Real<br>Santiago Montesinos. S. Farmacia. H. Arnau de Vilanova<br>Juan Antonio Barrera Ramirez.S. de Oncolog\u00eda. H. U. Elda<\/p>\n\n\n\n<p><\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"dia":[9],"class_list":["post-7688","mesa","type-mesa","status-publish","hentry","dia-dia-3"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama - Actualfarma 2025<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama - Actualfarma 2025\" \/>\n<meta property=\"og:description\" content=\"Pilar Vicente. S. Farmacia. H. U. Ciudad RealSantiago Montesinos. S. Farmacia. H. Arnau de VilanovaJuan Antonio Barrera Ramirez.S. de Oncolog\u00eda. H. U. Elda\" \/>\n<meta property=\"og:url\" content=\"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/\" \/>\n<meta property=\"og:site_name\" content=\"Actualfarma 2025\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/Actualfarma\/100066508608748\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-06T08:31:35+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/\",\"url\":\"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/\",\"name\":\"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama - Actualfarma 2025\",\"isPartOf\":{\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/#website\"},\"datePublished\":\"2025-05-10T09:08:24+00:00\",\"dateModified\":\"2025-06-06T08:31:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/actualfarma.es\/congreso-2025\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/#website\",\"url\":\"https:\/\/actualfarma.es\/congreso-2025\/\",\"name\":\"Actualfarma 2025\",\"description\":\"Jornadas farmacol\u00f3gicas\",\"publisher\":{\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/actualfarma.es\/congreso-2025\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/#organization\",\"name\":\"Actualfarma 2025\",\"url\":\"https:\/\/actualfarma.es\/congreso-2025\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/actualfarma.es\/congreso-2025\/wp-content\/uploads\/2022\/04\/logo.svg\",\"contentUrl\":\"https:\/\/actualfarma.es\/congreso-2025\/wp-content\/uploads\/2022\/04\/logo.svg\",\"caption\":\"Actualfarma 2025\"},\"image\":{\"@id\":\"https:\/\/actualfarma.es\/congreso-2025\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/people\/Actualfarma\/100066508608748\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama - Actualfarma 2025","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/","og_locale":"es_ES","og_type":"article","og_title":"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama - Actualfarma 2025","og_description":"Pilar Vicente. S. Farmacia. H. U. Ciudad RealSantiago Montesinos. S. Farmacia. H. Arnau de VilanovaJuan Antonio Barrera Ramirez.S. de Oncolog\u00eda. H. U. Elda","og_url":"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/","og_site_name":"Actualfarma 2025","article_publisher":"https:\/\/www.facebook.com\/people\/Actualfarma\/100066508608748\/","article_modified_time":"2025-06-06T08:31:35+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/","url":"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/","name":"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama - Actualfarma 2025","isPartOf":{"@id":"https:\/\/actualfarma.es\/congreso-2025\/#website"},"datePublished":"2025-05-10T09:08:24+00:00","dateModified":"2025-06-06T08:31:35+00:00","breadcrumb":{"@id":"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/actualfarma.es\/congreso-2025\/mesa\/trastuzumab-deruxtecan-y-sus-indicaciones-terapeuticas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/actualfarma.es\/congreso-2025\/"},{"@type":"ListItem","position":2,"name":"Del Her2+ al Her2 ultralow: redefiniendo el c\u00e1ncer de mama"}]},{"@type":"WebSite","@id":"https:\/\/actualfarma.es\/congreso-2025\/#website","url":"https:\/\/actualfarma.es\/congreso-2025\/","name":"Actualfarma 2025","description":"Jornadas farmacol\u00f3gicas","publisher":{"@id":"https:\/\/actualfarma.es\/congreso-2025\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/actualfarma.es\/congreso-2025\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/actualfarma.es\/congreso-2025\/#organization","name":"Actualfarma 2025","url":"https:\/\/actualfarma.es\/congreso-2025\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/actualfarma.es\/congreso-2025\/#\/schema\/logo\/image\/","url":"https:\/\/actualfarma.es\/congreso-2025\/wp-content\/uploads\/2022\/04\/logo.svg","contentUrl":"https:\/\/actualfarma.es\/congreso-2025\/wp-content\/uploads\/2022\/04\/logo.svg","caption":"Actualfarma 2025"},"image":{"@id":"https:\/\/actualfarma.es\/congreso-2025\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/Actualfarma\/100066508608748\/"]}]}},"_links":{"self":[{"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/mesa\/7688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/mesa"}],"about":[{"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/types\/mesa"}],"replies":[{"embeddable":true,"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/comments?post=7688"}],"version-history":[{"count":3,"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/mesa\/7688\/revisions"}],"predecessor-version":[{"id":7748,"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/mesa\/7688\/revisions\/7748"}],"wp:attachment":[{"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/media?parent=7688"}],"wp:term":[{"taxonomy":"dia","embeddable":true,"href":"https:\/\/actualfarma.es\/congreso-2025\/wp-json\/wp\/v2\/dia?post=7688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}